Edgewise Therapeutics (EWTX) Other Non-Current Assets (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Other Non-Current Assets of $695000.0 for Q1 2025, up 165.27% sequentially from $262000.0 in Q4 2024.
Edgewise Therapeutics (EWTX) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Other Non-Current Assets for 6 years, with the latest figure at $695000.0 in Q1 2025.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $695000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $695000.0 (changed N/A YoY) and the FY2024 annual result came in at $262000.0, down 24.71% from the prior year.
- Other Non-Current Assets rose to $695000.0 in Q1 2025 per EWTX's latest filing, from $262000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $695000.0 in Q1 2025 and troughed at $201000.0 in Q1 2021.
- A 5-year average of $368733.3 and a median of $295000.0 in 2021 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets jumped 178.11% in 2022, then sank 55.1% in 2023.
- Over 5 years, Other Non-Current Assets stood at $548000.0 in 2021, then plunged by 54.2% to $251000.0 in 2022, then surged by 38.65% to $348000.0 in 2023, then slipped by 24.71% to $262000.0 in 2024, then jumped by 165.27% to $695000.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $695000.0, $262000.0, and $262000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 4.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.36 Mn |
| Mar 31, 2025 | 695,000.00 |
| Dec 31, 2024 | 262,000.00 |
| Sep 30, 2024 | 262,000.00 |
| Jun 30, 2024 | 262,000.00 |
| Dec 31, 2023 | 348,000.00 |
| Sep 30, 2023 | 467,000.00 |
| Jun 30, 2023 | 419,000.00 |
| Mar 31, 2023 | 251,000.00 |
| Dec 31, 2022 | 251,000.00 |
| Sep 30, 2022 | 264,000.00 |
| Jun 30, 2022 | 447,000.00 |
| Mar 31, 2022 | 559,000.00 |
| Dec 31, 2021 | 548,000.00 |
| Sep 30, 2021 | 295,000.00 |
| Mar 31, 2021 | 201,000.00 |
| Dec 31, 2020 | 975,000.00 |